BRIEF published on 06/16/2026 at 19:48, 11 days 18 hours ago Valerio Therapeutics nomme un nouveau PDG et confirme les résolutions de son assemblée générale annuelle Biotechnologie Transition Du PDG Valerio Thérapeutique Gilles Besin Médicaments À Base D'ARN
BRIEF published on 06/16/2026 at 19:48, 11 days 18 hours ago Valerio Therapeutics Appoints New CEO and Confirms AGM Resolutions Biotechnology CEO Transition Valerio Therapeutics Gilles Besin RNA Medicines
PRESS RELEASE published on 06/16/2026 at 19:43, 11 days 18 hours ago Informations privilégiées / Autres communiqués Valerio Therapeutics nomme Gilles Besin au poste de Directeur Général et annonce les résultats de son Assemblée Générale Annuelle, marquant une nouvelle phase d'innovation dans les thérapies ciblées de précision Biotechnologie Assemblée Générale Directeur Général Valerio Therapeutics Gilles Besin
PRESS RELEASE published on 06/16/2026 at 19:43, 11 days 18 hours ago Inside Information / Other news releases Valerio Therapeutics appoints Gilles Besin as CEO, approved all resolutions at annual general meeting. Besin brings deep RNA and targeted delivery expertise to drive innovation Annual General Meeting Valerio Therapeutics Gilles Besin RNA Medicines Targeted Delivery
BRIEF published on 12/17/2025 at 11:02, 6 months 11 days ago Valerio Therapeutics Appoints Professor Eric Vivier as Board Observer Board Of Directors Immunology Valerio Therapeutics Professor Eric Vivier Oncology Strategy
BRIEF published on 12/17/2025 at 11:02, 6 months 11 days ago Valerio Therapeutics nomme le professeur Eric Vivier observateur au conseil d'administration Conseil D'administration Valerio Thérapeutique Immunologie Professeur Eric Vivier Stratégie En Oncologie
BRIEF published on 12/17/2025 at 11:02, 6 months 11 days ago Valerio Therapeutics Accueille le Professeur Eric Vivier au Conseil d'Administration Conseil D'administration Oncologie Valerio Therapeutics Immunologie Eric Vivier
BRIEF published on 12/17/2025 at 11:02, 6 months 11 days ago Valerio Therapeutics Welcomes Professor Eric Vivier to its Board of Directors Board Of Directors Oncology Immunology Valerio Therapeutics Eric Vivier
PRESS RELEASE published on 12/17/2025 at 10:57, 6 months 11 days ago Informations privilégiées / Autres communiqués Valerio Therapeutics annonce la désignation du Professeur Eric Vivier en qualité d'Observateur de son Conseil d’Administration. Le Professeur apportera son expertise en immunologie pour développer des traitements innovants en oncologie Conseil D'administration Valerio Therapeutics Immunologie Professeur Eric Vivier Observateur
PRESS RELEASE published on 12/17/2025 at 10:57, 6 months 11 days ago Inside Information / Other news releases Valerio Therapeutics appoints Prof. Eric Vivier as Observer to Board of Directors. Prof. Vivier, a renowned immunologist, will bring over 30 years of experience to drive innovative tumor treatment approaches Board Of Directors Valerio Therapeutics Professor Eric Vivier Immunologist Tumor Treatment
Published on 06/27/2026 at 16:50, 20 hours 59 minutes ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 1 day 12 hours ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 1 day 13 hours ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 1 day 14 hours ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 1 day 14 hours ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/27/2026 at 00:05, 1 day 13 hours ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 1 day 13 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 14 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 14 hours ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 1 day 14 hours ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
